Alcohol-induced Brain Injury
Conditions
Keywords
Alcohol-induced brain injury, atrophy, demyelination
Brief summary
Alcohol is one of most common harmful substance, and alcohol intake brings great burden on health worldwide. Excess alcohol intake may lead to alcohol-related brain injuries and cognitive impairment. Although both nerve growth factor and antioxidative treatment were effective to relieve alcohol-related injuries in central nervous system in the preclinical studies, there is no relevant clinical trial about their efficacy and safety on patients. Since nerve growth factor and one of the antioxidative medication, edaravone, have been used in some neural diseases in clinical trials, we tend to evaluate the efficacy and safety of nerve growth factor, or edaravone on alcohol-induced brain injuries. The study is a randomized-controlled study and the patients will be assigned into one of the following three groups randomly: (1) regular treatment (combination of vitamin B1, B6, C, E and mecobalamine) with nerve growth factor for 2 weeks and subsequently regular treatment for 6 months; (2) regular treatment (RT) with edaravone for 2 weeks and subsequently RT for 6 months; (3) RT alone for 6 months. The patients will be followed up for 6 months. Cognitive functions, recurrence of alcohol dependence, duration of abstention, alcohol intake, craving for alcohol and other psychological assessments will be recorded and compared among the 3 treatment groups and the efficacy of nerve growth factor or edaravone will be evaluated in our study.
Interventions
Intramuscular injection for 2 weeks
DRUGEdaravone
Intravenous injection for 2 weeks
DRUGCombination of vitamin B1, B6, C, E and mecobalamine
Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis as alcohol dependence according to DSM-IV criteria * MRI-proved demyelinating lesions or atrophy in the brain of the patient * No definite history of neurological diseases and psychological problems * Volunteer to participate the study, cooperate to be followed up
Exclusion criteria
* Acute withdrawal state and CIWA score \> 9 * With other neurological diseases and psychological problems * With ever brain trauma and damage * With other psychological medications or other substance dependence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive improvement | 2 weeks | Executive function by digit symbol substitute test (DSST) ranging from 0 to 90. Higher score indicates better executive function. |
| Cognitive assessment | 3 months | Cognitive assessment by Montreal Cognitive Assessment (MoCA) ranging from 0 to 30. Lower score indicates worse cognitive function. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alcohol intake | 2 weeks, 2 months, 3 months, 6 months | Diaries of alcohol intake in different time of the follow ups |
| Craving for alcohol | 2 weeks, 2 months, 3 months, 6 months | Craving assessment for alcohol by Obsessive Compulsive Drinking Scale (OCDS) ranging from 0 to 40. Higher score of OCDS indicates more desire for alcohol. |
| The rate of relapse of alcohol dependence after discharge from hospital | 2 months | Recurrence of alcohol dependence |
| Psychological assessment - Depression | 2 weeks, 2 months, 3 months, 6 months | Psychological assessment by Patient Health Questionnaire-9 (PHQ-9) ranging from 0 to 27. Higher score indicates more severer depression. |
| Psychological assessment - Sleep | 2 weeks, 2 months, 3 months, 6 months | Psychological assessment by Pittsburgh Sleep Quality Index (PSQI) ranging from 0 to 21. Higher score indicates worse sleep. |
| Psychological assessment - Anxiety | 2 weeks, 2 months, 3 months, 6 months | Psychological assessment by Generalized Anxiety Disorder-7 (GAD-7) ranging from 0 to 21. Higher score indicates more severer anxiety. |
| Duration of abstinence | 6 months | The total time or period without any intake of alcohol during follow ups |
Countries
China
Contacts
Primary ContactYing Peng, MD, PhD
Backup ContactHongxuan Wang, MD, PhD
Outcome results
None listed